The REVAMP trial: key questions remain - Authors' reply

Sant-Rayn Pasricha1, Ernest Moya2, Ricardo Ataide3

  • 1Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Diagnostic Haematology, The Royal Melbourne Hospital, Parkville, VIC, Australia; Clinical Haematology, The Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Parkville, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.

Lancet (London, England)
|January 6, 2024
PubMed
Summary

No abstract available in PubMed .